ArticleCell proliferation2019
IL-33 guides osteogenesis and increases proliferation and pluripotency marker expression in dental stem cells.
Article in Cell proliferation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Mechanisms of the IL-33/ST2 Signaling Axis in Regulating Bone Metabolism.Biomolecules · 2026Review
- Microenvironment-mediated stem cell fate in periodontal tissue remodeling and repair.Bioactive materials · 2026Review
- Abnormal circ-CDK8 expression affects periodontitis development by regulating let-7b-5p/MAP4K3 signaling.Regenerative therapy · 2026Article
- The paradigm shifts of periodontal regeneration strategy: From reparative manipulation to developmental engineering.Bioactive materials · 2025Review
- Chemical reprogramming culture for the expansion of salivary gland epithelial basal progenitor cells.Stem cell research & therapy · 2025Article
- Review
- IL-33 regulates adipogenesis via Wnt/β-catenin/PPAR-γ signaling pathway in preadipocytes.Journal of translational medicine · 2024Article
- A Single-Cell Raman Spectroscopy Analysis of Bone Marrow Mesenchymal Stem/Stromal Cells to Identify Inter-Individual Diversity.International journal of molecular sciences · 2022Article
- EZH2 Regulates Lipopolysaccharide-Induced Periodontal Ligament Stem Cell Proliferation and Osteogenesis through TLR4/MyD88/NF-Stem cells international · 2021Article
- Maxillofacial-Derived Mesenchymal Stem Cells: Characteristics and Progress in Tissue Regeneration.Stem cells international · 2021Review
- Exosome: Function and Application in Inflammatory Bone Diseases.Oxidative medicine and cellular longevity · 2021Review
- Inflammatory niche: Mesenchymal stromal cell priming by soluble mediators.World journal of stem cells · 2020Review
- In situ self-assembling Au-DNA complexes for targeted cancer bioimaging and inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway.Cell death & disease · 2019Article
- IL-33 guides osteogenesis and increases proliferation and pluripotency marker expression in dental stem cells.Cell proliferation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectivesSoluble IL-33 (interleukin (IL)-1-like cytokine) acts as endogenous alarm signal (alarmin). Since alarmins, besides activating immune system, act to restore tissue homeostasis, we investigated whether IL-33 exerts beneficial effects on oral stem cell pull. MATERIALS AND
methodsClonogenicity, proliferation, differentiation and senescence of stem cells derived from human periodontal ligament (PDLSCs) and dental pulp (DPSCs) were determined after in vitro exposure to IL-33. Cellular changes were detected by flow cytometry, Western blot, immunocytochemistry and semiquantitative RT-PCR.
resultsIL-33 stimulated proliferation, clonogenicity and expression of pluripotency markers, OCT-4, SOX-2 and NANOG, but it inhibited ALP activity and mineralization in both PDLSCs and DPSCs. Higher Ki67 expression and reduced β-galactosidase activity in IL-33-treated cells were demonstrated, whereas these trends were more conspicuous in osteogenic medium. However, after 7-day IL-33 pretreatment, differentiation capacity of IL-33-pretreated cells was retained, and increased ALP activity was observed in both cell types. Results showed that IL-33 regulates NF-κB and β-catenin signalling, indicating the association of these molecules with changes observed in IL-33-treated PDLSCs and DPSCs, particularly their proliferation, pluripotency-associated marker expression and osteogenesis.
conclusionsIL-33 treatment impairs osteogenesis of PDLSCs and DPSCs, while increases their clonogenicity, proliferation and pluripotency marker expression. After exposure to IL-33, osteogenic capacity of cells stayed intact. NF-κB and β-catenin are implicated in the effects achieved by IL-33 in PDLSCs and DPSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.